Scalper1 News
Gene-testerMyriad Genetics (MYGN) announced Friday that Medicare contract administrator Palmetto GBA has approved reimbursement coverage for Myriad’s Prolaris prostate cancer test for patients defined as low and very low risk. Myriad, though, also cut its revenue forecast for its fiscal Q1 ended Sept. 30 because of unanticipated costs as customers transition from the BRACAnalysis cancer test to its myRisk Hereditary Cancer test. Myriad now sees Q1 Scalper1 News
Scalper1 News